Immunomedics
 | The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. (May 2017) |
| Nasdaq: IMMU Russell 2000 Component | |
| Founded | 1982  |
| Headquarters | , United States |
| Website | https://immunomedics.com |
Immunomedics is a pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer.
Immunomedics was founded in July 1982 by David M. Goldenberg. Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[1] Dr. Behzad Aghazadeh was named Executive Chairman of the Board of Directors after Pehl's departure.[2]
Pipeline
- Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.
- Sacituzumab govitecan (IMMU-132) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease[3]
- Labetuzumab govitecan (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.
- Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.
- Milatuzumab is an anti-CD74 monoclonal antibody for autoimmune diseases.
- IMMU-114 is an anti-HLA-DR for hematological cancers.[4]
References
- ^ "Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach". endpts.com. Retrieved 2019-06-21.
- ^ "Iannone walks out on troubled Immunomedics a year after taking CMO job". fiercebiotech.com. Retrieved 2019-06-21.
- ^ "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments". FDA. 2020-04-22. Retrieved 2020-04-24.
- ^ "Corporate overview" (PDF). www.immunomedics.com. February 2018.
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |